Facebook
X
LinkedIn
Forward
Combatting Mycophenolate Risks in the Military Community: An Impactful Microlearning Approach to Strengthen the Delivery of REMS Compliant Care
This Mycophenolate REMS-compliant activity was designed to educate healthcare providers about the management of female patients of reproductive potential who are prescribed mycophenolate — particularly those professionals who care/may care for active military members and Veterans. Female members of the Military Community are at a high risk for autoimmune disease and are likely to be prescribed mycophenolate during their child-bearing years. Studies have shown that women in the Military Community often do not receive risk-lowering care when prescribed teratogenic medications like mycophenolate. This microlearning activity provides comprehensive education on reducing the risk of embryofetal toxicity associated with the use of mycophenolate during pregnancy in eight 15-minute episodes. Each episode will be presented as a video, audio-only file, or monograph to allow the learner to create an optional learning experience that best aligns with their learning style.
Target Audience
The intended audience includes physicians, nurse practitioners, nurses, physician assistants, pharmacists and other providers involved in the management of female patients of reproductive potential who are prescribed mycophenolate.
Learning Objectives
After completing of the educational activity, participants should be able to:
Identify the increased risks of first trimester pregnancy loss and congenital malformations associated with mycophenolate.
Develop strategies for educating females of reproductive potential about the risks of exposure to mycophenolate during pregnancy.
Plan the management of mycophenolate in females of reproductive potential.
Summarize provider responsibilities for reporting pregnancies to the Mycophenolate Pregnancy Registry and the importance of patient participation in the Mycophenolate Pregnancy Registry.
Commercial Support
This activity is supported by an independent educational grant from the Mycophenolate REMS Group. This activity is intended to be fully compliant with the Mycophenolate REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
Alicia Y. Christy MD, MHSCR (Chair)
Colonel (retired)
Dr Christy has nothing to disclose.
Evelyn Lewis, MD, MA, FAAFP, DABDA
President and Chair, Veterans Health and Wellness Foundation
Adjunct Associate Professor, Rutgers RWJMS
Newnan, GA
Dr Lewis has nothing to disclose.
Jessica Lee Lin, MPAP
Physician Assistant
University of California, San Diego
San Diego, CA
Ms. Lee has nothing to disclose.
Monica L Reynolds, MD, MSCR
Associate Professor
UNC Nephrology and Hypertension
Dr Reynolds has the following financial relationship: Speaker - Travere Therapeutics
Stephanie Widmer, DO
Medical Toxicologist & Attending Physician
St John's Riverside Hospital, Yonkers, NY
Dr Widmer has nothing to disclose.
Hailey Ehmke - Nurse Student
Ms. Ehmke has nothing to disclose
Calla Ehmke - Patient
Ms. Ehmke has nothing to disclose
Alexandra Poch - Patient
Ms. Poch has nothing to disclose
Dorothy Caputo, MA, BSN, RN
VP, Healthcare Continuing Education and Operations
AKH Inc., Advancing Knowledge in Healthcare
Austin, TX
Ms. Caputo has nothing to disclose.
Deborah C. Clark, Ph.D.
Sr. Director, Professional Development and Partnerships
AKH Inc., Advancing Knowledge in Healthcare
Austin, TX
Ms. Clark has nothing to disclose.
Planners and Reviewers
Dorothy Caputo, MA, BSN, RN (President, AKH Inc.) has nothing to disclose.
Michele Bielarski, RN (Reviewer) has nothing to disclose.
Bernadette Makar, MSN, APRN-BC, NP-C (Reviewer) has nothing to disclose.
AKH Inc, ACMT, VHWF Staff and Planners have nothing to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare, Veterans Health and Wellness Foundation (VHWF) and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 2 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 2 contact hours.
Nursing
Credit being awarded: 2 ANCC contact hours
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid until 10/27/2026. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare, Veterans Health and Wellness Foundation (VHWF) and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 2 contact hour(s) (which includes 2 hour(s) of pharmacology).
Available Credit
- 2.00 AANP
- 2.00 AANP Pharmacology Contact Hours
- 2.00 AAPA Category 1 CME
- 2.00 ACPE Pharmacist
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC
- 2.00 Attendance